Merrem Related Published Studies
Well-designed clinical trials related to Merrem (Meropenem)
Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. [2009.07]
A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus. [2006.08]
Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. [2006.07]
Timing of antibiotic prophylaxis in acute pancreatitis: a controlled randomized study with meropenem. [2006.06]
Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors. [2006.04]
The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. [2005.10]
Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. [2005.09]
Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. [2005.05]
Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. [2005.04]
Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. [2005]
Well-designed clinical trials possibly related to Merrem (Meropenem)
Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. [2008.03]
Correlates of clinical failure in ventilator-associated pneumonia: insights from a large, randomized trial. [2008.03]
Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. [2008.01]
Empiric antibiotic therapy for suspected ventilator-associated pneumonia: A systematic review and meta-analysis of randomized trials. [2007.11.13]
[Effectiveness of switch therapy for peritonitis] [2007.08]
Impact of carbapenem administration on systemic endotoxemia in patients with severe sepsis and Gram-negative bacteremia. [2006.10]
Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. [2006.02]
Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. [2005.07]
Other research related to Merrem (Meropenem)
Meropenem pharmacokinetics in the newborn. [2009.09]
Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever. [2009.08]
Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. [2009.08]
[Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly] [2009.07]
Meropenem-clavulanate: a new strategy for the treatment of tuberculosis? [2009.07]
Evaluation of meropenem alone and combined with rifampin in the guinea pig model of pneumococcal meningitis. [2009.07]
Mortality rate in neonates infected with extended-spectrum beta lactamase-producing Klebsiella species and selective empirical use of meropenem. [2009.06]
Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. [2009.06]
Chromobacterium violaceum endocarditis and hepatic abscesses treated successfully with meropenem and ciprofloxacin. [2009.04.06]
Effect of concomitant administration of meropenem and valproic acid in an elderly Chinese patient. [2009.02]
Meropenem use and colonization by antibiotic-resistant Gram-negative bacilli in a pediatric intensive care unit. [2009.01]
Effect of early antibiotic prophylaxis with ertapenem and meropenem in experimental acute pancreatitis in rats. [2009]
Effectiveness of meropenem for the treatment of aspiration pneumonia in elderly patients. [2009]
The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients. [2008.10]
Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. [2008.09.15]
Pharmacokinetic and pharmacodynamic properties of meropenem. [2008.09.15]
Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate. [2008.09]
[Obtain best usage of meropenem dose in severe infections. Results of an observational multicenter study] [2008.09]
Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia. [2008.09]
Experimental study of meropenem in the therapy of cephalosporin-susceptible and -resistant pneumococcal meningitis. [2008.08]
Bioequivalence, antibacterial activity and therapeutic outcome of a generic meropenem (Mapenem). [2008.07]
[The impact of different renal function measuring methods on the dosages of meropenem, piperacillin/tazobactam and cefepime in critically ill patients] [2008.07]
The relationship between the daily dosage of the carbapenem meropenem (MEPM) and MEPM-resistant Pseudomonas aeruginosa. [2008.06]
Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. [2008.06]
Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study. [2008.05]
Safety of meropenem in patients reporting penicillin allergy: lack of allergic cross reactions. [2008.04]
In vitro evaluation of the antimicrobial activity of meropenem in combination with polymyxin B and gatifloxacin against Pseudomonas aeruginosa and Acinetobacter baumannii. [2008.04]
Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. [2008.03]
Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. [2008.03]
Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. [2008.02.23]
Tolerability of meropenem in children with IgE-mediated hypersensitivity to penicillins. [2008.02]
Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. [2008.02]
Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. [2008]
Meropenem: a review of its use in the treatment of serious bacterial infections. [2008]
Clinical outcomes and cost minimization with an alternative dosing regimen for meropenem in a community hospital. [2007.12]
[Use of Meropenem in preterm newborns. Survey of the literature and case series] [2007.12]
[Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory] [2007.12]
Quantification of meropenem in plasma and cerebrospinal fluid by micellar electrokinetic capillary chromatography and application in bacterial meningitis patients. [2007.09.01]
Safe use of meropenem in a patient with a possible nonimmediate allergy to imipenem. [2007.09]
Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. [2007.08.31]
Interaction between valproate and meropenem: a retrospective study. [2007.07]
Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem. [2007.06]
[Clinical efficacy of prolonged (4 hour) drip infusion of meropenem against severe pneumonia] [2007.06]
Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy. [2007.06]
Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. [2007.05]
Mechanisms of resistance to carbapenems in meropenem- resistant Acinetobacter isolates from clinical samples. [2007.04]
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. [2007.04]
Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant Acinetobacter baumannii multifocal infection. A case report. [2007.03]
Brief communication: tolerability of meropenem in patients with IgE-mediated hypersensitivity to penicillins. [2007.02.20]
Successful treatment of life-threatening melioidosis with activated protein C and meropenem. [2007.02]
Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. [2007.02]
Meropenem -valproic acid interaction in patients with cefepime-associated status epilepticus. [2007.01.01]
Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. [2007]
[Administration method of meropenem on the basis of PK/PD (pharmacokinetics/pharmacodynamics) in consideration of renal function] [2006.12]
Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea. [2006.10]
Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. [2006.10]
Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). [2006.09]
Mechanical effects of the use of vancomycin and meropenem in acrylic bone cement. [2006.08]
Epileptic seizures caused by low valproic acid levels from an interaction with meropenem. [2006.08]
In vitro antimicrobial activity of liposomal meropenem against Pseudomonas aeruginosa strains. [2006.06.06]
[Clinical effect of continuous infusion of meropenem on bacterial pneumonia in the elderly] [2006.06]
Prospective drug utilization evaluation of three broad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and meropenem. [2006.06]
Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care. [2006.03]
Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. [2006.02]
Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients. [2006.01]
Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. [2006.01]
Efficacy and safety of meropenem plus tobramycin followed by meropenem plus vancomycin for treating peritonitis in patients on continuous ambulatory peritoneal dialysis. [2006]
Cure of persistent, post-appendectomy Klebsiella pneumoniae septicaemia with continuous intravenous administration of meropenem. [2006]
Pharmacodynamic evaluation of meropenem and cefotaxime for pediatric meningitis: a report from the OPTAMA program. [2006]
[Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004] [2005.12]
An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004. [2005.12]
Transfer of meropenem in the ex vivo human placenta perfusion model. [2005.12]
Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. [2005.12]
Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients. [2005.11]
Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004). [2005.10]
Serratia marcescens prosthesis infection successfully treated with meropenem after imipenem failure. [2005.08]
An outbreak of SHV-5 producing Klebsiella pneumoniae in a neonatal intensive care unit; meropenem failed to avoid fecal colonization. [2005.07]
Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem. [2005.07]
Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment. [2005.07]
An evaluation of an optimal sampling strategy for meropenem in febrile neutropenics. [2005.07]
Meropenem in the treatment of febrile neutropenic children. [2005.06]
Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections. [2005.05]
Seizure worsening caused by decreased serum valproate during meropenem therapy. [2005.05]
|
